Analytical strategies for identifying drug metabolites

被引:263
作者
Prakash, Chandra
Shaffer, Christopher L.
Nedderman, Angus
机构
[1] Pfizer Global Res & Dev, Groton, CT 06340 USA
[2] Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
关键词
biotransformation; LC-MS/MS; metabolites; structural characterization; derivatization; HID-exchange; LC-NMR;
D O I
10.1002/mas.20128
中图分类号
O433 [光谱学];
学科分类号
0703 [化学]; 070302 [分析化学];
摘要
With the dramatic increase in the number of new chemical entities (NCEs) arising from combinatorial chemistry and modem high-throughput bioassays, novel bioanalytical techniques are required for the rapid determination of the metabolic stability and metabolites of these NCEs. Knowledge of the metabolic site(s) of the NCEs in early drug discovery is essential for selecting compounds with favorable pharmacokinetic credentials and aiding medicinal chemists in modifying metabolic "soft spots". In development, elucidation of biotransformation pathways (of a drug candidate by identifying its circulatory and excretory metabolites is vitally important to understand its physiological effects. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) have played an invaluable role in the structural characterization and quantification of drug metabolites. Indeed, liquid chromatography (LC) coupled with atmospheric pressure ionization (API) MS has now become the most powerful tool for the rapid detection, structure elucidation, and quantification of drug-derived material within various biological fluids. Often, however MS alone is insufficient to identify the exact position of oxidation, to differentiate isomers, or to provide the precise structure Of unusual and/or unstable metabolites. In addition, an excess of endogenous material in biological samples often suppress the ionization of drug-related material complicating metabolite identification by MS. In these cases, multiple analytical and wet chemistry techniques, such as LC-NMR, enzymatic hydrolysis, chemical derivatization, and hydrogen/deuterium-exchange (HID-exchange) combined with MS are used to characterize the novel and isomeric metabolites of drug candidates. This review describes sample preparation and introduction strategies to minimize ion suppression by biological matrices for metabolite identification studies, the application of various LC-tandem MS (LC-MS/MS) techniques for the rapid quantification and identification of drug metabolites, and future trends in this field. (c) 2007 Wiley Periodicals, Inc.,
引用
收藏
页码:340 / 369
页数:30
相关论文
共 183 条
[1]
Alavijeh MS, 2004, IDRUGS, V7, P755
[2]
Derivatization of ethinylestradiol with dansyl chloride to enhance electrospray ionization: Application in trace analysis of ethinylestradiol in rhesus monkey plasma [J].
Anari, MR ;
Bakhtiar, R ;
Zhu, B ;
Huskey, S ;
Franklin, RB ;
Evans, DC .
ANALYTICAL CHEMISTRY, 2002, 74 (16) :4136-4144
[3]
Bridging cheminformatic metabolite prediction and tandem mass spectrometry [J].
Anari, MR ;
Baillie, TA .
DRUG DISCOVERY TODAY, 2005, 10 (10) :711-717
[4]
[Anonymous], 2005, DRUG METAB DISPOS, DOI DOI 10.1124/dmd.105.005041
[5]
The potential of inductively coupled plasma mass spectrometry detection for high-performance liquid chromatography combined with accurate mass measurement of organic pharmaceutical compounds [J].
Axelsson, BO ;
Jörnten-Karlsson, M ;
Michelsen, P ;
Abou-Shakra, F .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2001, 15 (06) :375-385
[6]
Ayrton J, 1997, RAPID COMMUN MASS SP, V11, P1953, DOI 10.1002/(SICI)1097-0231(199712)11:18<1953::AID-RCM102>3.0.CO
[7]
2-Z
[8]
Drug metabolites in safety testing [J].
Baillie, TA ;
Cayen, MN ;
Fouda, H ;
Gerson, RJ ;
Green, JD ;
Grossman, SJ ;
Klunk, LJ ;
LeBlanc, B ;
Perkins, DG ;
Shipley, LA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) :188-196
[9]
BAILLIE TA, 2003, DRUG METABOLIZING EN, P147
[10]
Barker J, 1999, RAPID COMMUN MASS SP, V13, P285, DOI 10.1002/(SICI)1097-0231(19990228)13:4<285::AID-RCM469>3.3.CO